Gaudium IVF and Women Health Ltd
Incorporated in March 2015, Gaudium IVF and Women Health Limited have engaged in In Vitro Fertilization (IVF) treatments throughout India.[1]
- Market Cap ₹ 884 Cr.
- Current Price ₹ 121
- High / Low ₹ 133 / 69.2
- Stock P/E 48.0
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE 47.8 %
- ROE 51.6 %
- Face Value ₹ 5.00
Pros
- Company has a good return on equity (ROE) track record: 3 Years ROE 50.0%
Cons
- Debtor days have increased from 87.3 to 146 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Healthcare Service Provider
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| 44 | 46 | 59 | |
| 24 | 27 | 31 | |
| Operating Profit | 20 | 19 | 28 |
| OPM % | 45% | 41% | 48% |
| 0 | 0 | 0 | |
| Interest | 0 | 1 | 2 |
| Depreciation | 1 | 2 | 2 |
| Profit before tax | 18 | 16 | 25 |
| Tax % | 26% | 38% | 25% |
| 13 | 10 | 19 | |
| EPS in Rs | 133.91 | 100.28 | 3.03 |
| Dividend Payout % | 48% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 28% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 87% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 50% |
| Last Year: | 52% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| Equity Capital | 0.99 | 0.99 | 31 |
| Reserves | 22 | 26 | 15 |
| 10 | 17 | 21 | |
| 2 | 7 | 9 | |
| Total Liabilities | 35 | 51 | 75 |
| 16 | 18 | 18 | |
| CWIP | 0 | 0 | 7 |
| Investments | 1 | 1 | 6 |
| 18 | 31 | 44 | |
| Total Assets | 35 | 51 | 75 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| 24 | 3 | 8 | |
| -14 | -5 | -15 | |
| 4 | -1 | 2 | |
| Net Cash Flow | 13 | -3 | -5 |
| Free Cash Flow | 11 | 1 | -0 |
| CFO/OP | 145% | 28% | 46% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| Debtor Days | 7 | 108 | 146 |
| Inventory Days | 101 | 141 | 170 |
| Days Payable | 83 | 85 | 99 |
| Cash Conversion Cycle | 26 | 164 | 218 |
| Working Capital Days | -54 | -22 | 46 |
| ROCE % | 44% | 48% |
Documents
Announcements
-
Clarification On Price Movement
16 Apr - Company clarified price movement was market-driven and disclosed no new price-sensitive information.
- Clarification sought from Gaudium IVF and Women Health Ltd 16 Apr
-
Intimation Regarding Change Of Corporate Identification Number Of The Company
15 Apr - Company CIN changed to L85100DL2015PLC278296; status updated from unlisted to listed.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
10 Apr - Compliance certificate under Regulation 74(5) for quarter ended March 31, 2026; no rematerialisation requests.
-
Gaudium IVF And Women Health Limited Has Updated The Exchange On The Query Received From BSE Limited Vide Its Email Dated April 07 2026 Seeking Additional Details For Corporate Announcement Dated April 06 2026 Filed Under Regulation 30 Of SEBI (LODR) Regu
7 Apr - Bombay High Court disposed Neomile petition on April 2, 2026; Justice Nitin Jamdar appointed sole arbitrator.
Business Profile[1][2]
The company operates in the Assisted Reproductive Technology (ART) and IVF segment in India, following a hub-and-spoke model across 30+ locations (7 hubs and 28 spokes). It also runs a 15-bed day-care hospital in Janakpuri (Delhi NCR) and operates an in-house pharmacy through its wholly owned subsidiary, Gaudium International Pvt. Ltd.